Melissa Epperly - Feb 12, 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Stock symbol
ZNTL
Transactions as of
Feb 12, 2024
Transactions value $
-$29,435
Form type
4
Date filed
2/12/2024, 08:22 PM
Previous filing
Feb 5, 2024
Next filing
Apr 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$29.4K -2.57K -0.57% $11.44 451K Feb 12, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.